25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
12 citations
,
July 2012 in “Journal of cutaneous medicine and surgery” Adalimumab was safe but mostly ineffective for severe alopecia areata.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
September 2025 in “Clinical and Experimental Rheumatology”
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
10 citations
,
January 2020 in “Journal of Materials Chemistry B” The biofilm enhances skin healing by promoting cell growth and blood vessel formation.
July 2026 in “Journal of the European Academy of Dermatology and Venereology” July 2024 in “Journal of Investigative Dermatology” Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
4 citations
,
January 1970 in “Journal of Bangladesh College of Physicians and Surgeons” Early diagnosis and genetic counseling are crucial for managing adrenoleukodystrophy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
July 2004 in “Journal of Clinical Oncology” Isolated hyperthermic chemotherapy perfusion for limb melanoma is safe and effective with manageable side effects.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
June 2026 in “British Journal of Dermatology” Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.
1 citations
,
January 2021 PRP is effective for treating patchy alopecia areata.
36 citations
,
January 2010 in “International Journal of Trichology” Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
January 2024 in “International Journal of Dermatology” Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.
July 2021 in “International journal of dermatology, venereology and leprosy sciences” Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.
23 citations
,
June 1950 in “American journal of diseases of children” Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.
30 citations
,
April 2007 in “Journal of Leukocyte Biology” Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
February 2024 in “Journal of dermatology” CGF therapy may help hair regrowth and improve scars in DLE patients.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
August 2025 in “Galen Medical Journal” Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.